Non-small cell lung cancer · line 3 · Docetaxel + Ramucirumab (REVEL) — 2L+ NSCLC post-platinum / post-ICI
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | standard |
| Linked regimen | REG-DOCETAXEL-RAMUCIRUMAB |
| ID | IND-NSCLC-3L-DRIVER-BEYOND-2L |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. 3L+ pathway for driver-positive NSCLC after exhaustion of 1L targeted + 2L chemoimmunotherapy/IO. Re-biopsy recommendation embedded in rationale. Trial enrollment consideration alongside empirical regimens.
Used By
No reverse references found in the YAML corpus.